Generic Name and Formulations:
Acamprosate calcium 333mg; e-c tabs.
Indications for CAMPRAL:
Maintenance of abstinence from alcohol in alcohol-dependent patients who are abstinent at treatment initiation, in conjunction with psychosocial support.
666mg 3 times daily. Renal impairment (CrCl 30–50mL/min): initially 333mg 3 times daily. Begin therapy during abstinence; continue during relapse.
Severe renal impairment (CrCl≤30mL/min). Sulfite allergy.
Moderate renal impairment (CrCl 31–50mL/min); reduce dose. Not a treatment for withdrawal symptoms. Monitor for suicidal ideation. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
GI upset, myalgia/arthralgia, headache, rash, syncope, impotence, edema, palpitations; rare: kidney failure, suicidality.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Treatment Linked to Cognitive Scores in Breast Cancer Survivors